

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ab&B Bio-Tech CO., LTD. JS

江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2627)

QUARTERLY UPDATE ON RESUMPTION PROGRESS AND CONTINUED SUSPENSION OF TRADING

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the “**Company**”, together with its subsidiary, the “**Group**”) pursuant to Rule 13.09 and Rule 13.24A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the Company's announcements dated April 1, 14, 24 and 29, 2026, May 27, 2026, June 5, 2026, and August 31, 2026 in relation to, among other things, (i) the delay in publication of the 2025 Annual Results and the postponement of the Board meeting; (ii) the suspension of trading; (iii) the change of auditor; (iv) the resumption guidance for the resumption of trading in the shares of the Company; (v) the appointment of independent investigator and independent internal control consultant; and (vi) the delay in publication of the 2026 Interim Results (collectively the “**Announcements**”). Unless otherwise defined or the context otherwise requires, capitalized terms in this announcement shall have the same meanings as those defined in the Announcements.

QUARTERLY UPDATE ON RESUMPTION PROGRESS

As disclosed in the Company's announcement dated April 29, 2026, the Stock Exchange has prescribed the following Resumption Guidance:

- (i) conduct an appropriate independent forensic investigation into the Fund Investments (including the initial investments and re-investments), the Consultancy Payments, and any other investments or payments of a similar nature or giving rise to similar concerns; assess the impact on the Company's business operations and financial position; announce the findings; and take appropriate remedial actions;
- (ii) demonstrate that there is no reasonable regulatory concern about the integrity, competence and/or character of the Group's management and/or any persons with substantial influence over the Company's management and operations, which may pose a risk to investors and damage market confidence;

- (iii) engage an independent internal control consultant to conduct an independent internal control review and demonstrate that: (a) the material deficiencies identified in relation to the trading suspension have been rectified and all necessary remedial measures have been implemented; and (b) the internal controls of the Company are adequate and effective to serve their purposes and enable the Company to comply with the Listing Rules in all material aspects, including but not limited to financial reporting, cash management, disclosure and compliance relating to notifiable and connected transactions and disclosure of material information;
- (iv) publish all outstanding financial results required under the Listing Rules and address any audit modifications;
- (v) demonstrate the Company's compliance with Rule 13.24; and
- (vi) inform the market of all material information for the Company's shareholders and investors to appraise the Company's position.

Pursuant to Rule 13.24A of the Listing Rules, the Board hereby updates the Shareholders and potential investors that, as at the date of this announcement, the latest developments of the Company and the progress of fulfilling the Resumption Guidance are as follows:

(i) Independent Forensic Investigation

As disclosed in the Company's announcement dated June 5, 2026, the Audit Committee has engaged Baker Tilly Aranea Forensic Investigation Company Limited ("**BTA**") to conduct a forensic investigation and report on the Fund Investments and Consultancy Payments (the "**Investigation**").

As at the date of this announcement, the Investigation has commenced and is ongoing. The Company will publish further announcement(s) to keep the Shareholders and potential investors informed of the key findings and results of the Investigation as and when appropriate.

The Company will take appropriate actions and measures as soon as practicable upon completion of the Investigation to assess whether there is any regulatory concern about the management integrity and/or the integrity of any persons with substantial influence over the Company's management and operations.

(ii) Internal Control Review

As disclosed in the Company's announcement dated June 5, 2026, the Audit Committee has engaged Cheng & Cheng Risk Advisory Services Limited ("**CCRA**") to conduct an internal control review in relation to, among other things, the Fund Investments and Consultancy Payments (the "**Internal Control Review**").

As at the date of this announcement, the Internal Control Review has commenced and is ongoing. The Company will publish further announcement(s) to keep the Shareholders and potential investors informed of the key findings and results of the Internal Control Review as and when appropriate.

(iii) Outstanding Financial Results

As disclosed in the Company's announcement dated April 14, 2026, Deloitte Touche Tohmatsu ("**DTT**") resigned as auditor of the Company with immediate effect on April 13, 2026. As disclosed in the Company's announcements dated April 24, 2026 and May 27, 2026, the Company appointed CLA Prism Hong Kong Limited (previously known as Prism Hong Kong Limited) ("**Prism**") as its auditors to fill the vacancy arising from DTT's resignation with effect from May 27, 2026. As at the date of this announcement, Prism has commenced the audit work on the 2025 Annual Results and has been conducting major audit procedures including confirmations, review of accounting vouchers and review of valuation. The completion of the 2025 Audit is subject to completion of audit procedures and the findings of the Audit Committee-led reviews.

As disclosed in the Company's announcement dated August 31, 2026, as the Company has not yet published the 2025 Annual Results, and the 2026 Interim Results will contain certain financial information from the 2025 Annual Results, the publication of the 2026 Interim Results and the dispatch of the 2026 Interim Report has been delayed. It is expected that the 2026 Interim Results will be published after the publication of the 2025 Annual Results.

The Company will separately announce in due course (i) the date of the Board meeting to consider and approve the 2025 Annual Results and the 2026 Interim Results; (ii) the date of publication of the 2025 Annual Results Announcement; (iii) the date of publication of the 2026 Interim Results; and (iv) any other significant developments.

UPDATE ON BUSINESS OPERATION

The Company is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines adopting new technical methods. In formulating our pipeline, the Company closely tracks global trends in infectious disease incidence and vaccine R&D, with a strategic focus on premium vaccines, aiming to replace traditional vaccines and imported vaccines in China and establish our presence in international markets. The Company's range of products includes, but is not limited to, the quadrivalent subunit influenza vaccine, the trivalent subunit influenza vaccine and the lyophilized human rabies vaccine candidate, along with other vaccine candidates.

As at the date of this announcement, the Group has maintained its normal day-to-day business operations in all material respects. The Board considers that the Group's business has substance and is viable and sustainable in the long term, and that the Group has a sufficient level of operations and assets of sufficient value to support its operations and its continued listing on the Stock Exchange. The research and development and commercialization of the Group's principal products are progressing as planned.

The Group will continue to review and manage its existing businesses with a view to improving its business operations and financial position. Any material development in relation to the business operations of the Group will be disclosed in accordance with the Listing Rules. The Company will continue to actively seek to resume trading of its Shares on the Stock Exchange as soon as practicable.

CONTINUED SUSPENSION OF TRADING

Trading in the H Shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on Wednesday, April 1, 2026 and will remain suspended until further notice.

Further announcement(s) will be made by the Company to keep the Shareholders and potential investors informed of any material development in this regard as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai
Executive Director, chairman of our Board and general manager

Hong Kong, September 30, 2026

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai and Mr. HE Yiming as executive Directors; (ii) Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Mr. LI Jianjun, Mr. CHEN Chengbei and Ms. LUI Mei Ka as independent non-executive Directors.